Literature DB >> 11011066

Neurotrophic factors in Alzheimer's and Parkinson's disease brain.

G J Siegel1, N B Chauhan.   

Abstract

The biomedical literature on the subject of neurotrophic growth factors has expanded prodigiously. This essay reviews neurotrophic factors (NTF) and their receptors in Alzheimer's disease (AD) and Parkinson's disease (PD) brain and recent updates on receptor signaling. The hypotheses for specific NTF involvement in neurodegenerative diseases in human and as potential therapy are based mainly on experimental animal and in vitro models. There are wide gaps in information on regional synthesis and cell contents of NTFs and their receptors in human brain. Observations on AD brain indicate increases in NGF and decreases in BDNF in surviving neurons of hippocampus and certain neocortical regions and decreases in TrkA in cortex and nucleus basalis. In PD brain, the few data available indicate decreases in neuronal content of GDNF and bFGF in surviving substantia nigra dopaminergic neurons. There are very few data regarding age-dependent effects on NTFs and on their receptors in human brain. Since NTFs in neurons are subject to retrograde and, in at least some cases, to anterograde transport from and to target neurons, their effects may be related to synthesis in local or remote sites or to changes in axoplasmic transport. Also, certain NTFs and their receptors are found to be expressed in activated glia. Thus, comparative in situ data for transcription levels and protein contents for NTFs and their receptors in both sites of neuronal origin and termination in human brain are needed to understand their potential roles in treating human diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11011066     DOI: 10.1016/s0165-0173(00)00030-8

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  131 in total

1.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 2.  The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.

Authors:  Costantino Iadecola
Journal:  Acta Neuropathol       Date:  2010-07-11       Impact factor: 17.088

3.  Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses.

Authors:  Wayne Chadwick; Yu Zhou; Sung-Soo Park; Liyun Wang; Nicholas Mitchell; Matthew D Stone; Kevin G Becker; Bronwen Martin; Stuart Maudsley
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

4.  GABA and 5-HT chitosan nanoparticles decrease striatal neuronal degeneration and motor deficits during liver injury.

Authors:  J Shilpa; C S Paulose
Journal:  J Mater Sci Mater Med       Date:  2014-03-30       Impact factor: 3.896

5.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

6.  Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model.

Authors:  Motoyuki Kohjima; Yuxiang Sun; Lawrence Chan
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

7.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

8.  Morphine-induced apoptosis in the ventral tegmental area and hippocampus after the development but not extinction of reward-related behaviors in rats.

Authors:  Yasaman Razavi; Shabnam Zeighamy Alamdary; Seyedeh-Najmeh Katebi; Fariba Khodagholi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.046

Review 9.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury.

Authors:  Antonio Chiaretti; Marco Piastra; Giancarlo Polidori; Concezio Di Rocco; Elena Caresta; Alessia Antonelli; Tiziana Amendola; Luigi Aloe
Journal:  Intensive Care Med       Date:  2003-07-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.